BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 19298236)

  • 1. Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.
    Yuan SH; Ge WH; Huo J; Wang XH
    Fundam Clin Pharmacol; 2009 Apr; 23(2):189-96. PubMed ID: 19298236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats.
    Kim CK; Han JH
    J Microencapsul; 1995; 12(4):437-46. PubMed ID: 8583318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic changes of methotrexate after intravenous administration to uranyl nitrate-induced acute renal failure rats.
    Park JM; Moon CH; Lee MG
    Res Commun Mol Pathol Pharmacol; 1996 Sep; 93(3):353-62. PubMed ID: 8896046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life-threatening interaction between the root extract of Pueraria lobata and methotrexate in rats.
    Chiang HM; Fang SH; Wen KC; Hsiu SL; Tsai SY; Hou YC; Chi YC; Chao PD
    Toxicol Appl Pharmacol; 2005 Dec; 209(3):263-8. PubMed ID: 15936791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse erythrocyte carriers osmotically loaded with methotrexate.
    Kruse CA; Freehauf CL; Patel KR; Baldeschwieler JD
    Biotechnol Appl Biochem; 1987 Apr; 9(2):123-40. PubMed ID: 3593543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of methotrexate in the guinea pig.
    Schlatter J; Di Blasi-Bouvet S; Raynaud F; Cisternino S
    Cell Mol Biol (Noisy-le-grand); 1999 May; 45(3):363-8. PubMed ID: 10386793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate.
    Kurmi BD; Gajbhiye V; Kayat J; Jain NK
    J Pharm Sci; 2011 Jun; 100(6):2311-20. PubMed ID: 21491447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of methotrexate after intravenous administration of methotrexate-loaded proliposomes to rats.
    Park JM; Ahn BN; Yoon EJ; Lee MG; Shim CK; Kim CK
    Biopharm Drug Dispos; 1994 Jul; 15(5):391-407. PubMed ID: 7981428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier.
    Han JH; Oh YK; Kim DS; Kim CK
    Int J Pharm; 1999 Oct; 188(1):39-47. PubMed ID: 10528081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy.
    Cole PD; Zebala JA; Alcaraz MJ; Smith AK; Tan J; Kamen BA
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):826-34. PubMed ID: 16170572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
    Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localization and distribution of magnetic chemotherapeutic drugs with magnetic targeting in rat brain.
    Li AM; Zhang CX; Fu XP; Zhang ZW; Xue QH; Yan RM; Yi LH
    Chin Med J (Engl); 2005 May; 118(10):824-7. PubMed ID: 15989762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced systemic availability of methotrexate in the presence of morin in rats.
    Hong SS; Jin MJ; Han HK
    Biopharm Drug Dispos; 2008 May; 29(4):189-93. PubMed ID: 18240155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian calculation of methotrexate clearance after low dose intramuscular administration in patients with rheumatoid arthritis.
    Monjanel-Mouterde S; Lafforgue P; Blanc A; Catalin J; Aquaviva PC; Durand A
    J Rheumatol; 1998 Jul; 25(7):1276-81. PubMed ID: 9676756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PEGylated polyamidoamine dendrimer/methotrexate complex: pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodents].
    Kong SY; Tang GT; Pei YY; Jiang YY
    Yao Xue Xue Bao; 2009 Jan; 44(1):85-90. PubMed ID: 19350828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and passive target of 5-fluorouracil solid lipid nanoparticles.
    Du B; Yan Y; Li Y; Wang S; Zhang Z
    Pharm Dev Technol; 2010; 15(4):346-53. PubMed ID: 19769532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of topical delivery of methotrexate by electroporation.
    Wong TW; Zhao YL; Sen A; Hui SW
    Br J Dermatol; 2005 Mar; 152(3):524-30. PubMed ID: 15787822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis.
    Dalrymple JM; Stamp LK; O'Donnell JL; Chapman PT; Zhang M; Barclay ML
    Arthritis Rheum; 2008 Nov; 58(11):3299-308. PubMed ID: 18975321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and tissue distribution of 5-fluorouracil encapsulated by galactosylceramide liposomes in mice.
    Jin Y; Li J; Rong LF; Lü XW; Huang Y; Xu SY
    Acta Pharmacol Sin; 2005 Feb; 26(2):250-6. PubMed ID: 15663907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability.
    Dhanikula RS; Argaw A; Bouchard JF; Hildgen P
    Mol Pharm; 2008; 5(1):105-16. PubMed ID: 18171013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.